Posts Tagged ‘cancer stem cells’

By all means, target the CSCs – but leave the normal stem cells out of it!

Author: Sara M. Nolte, 05/19/15

. I’ve spent a number of posts going on and on about how targeting cancer stem cells (CSCs) is the next big thing for cancer therapies, and how important it is that we study and learn all we can about them (know your enemy, right?). All of this has probably left you with at least…Read more

What’s in a name? A cancer stem cell by any other name is still a stem cell – or is it?

Author: Sara M. Nolte, 03/23/15

> I have previously written about the phrase “cancer stem cell,” and how it can be misleading for researchers and the public alike. As scientists, we go through great pains to be specific in our use of ‘cancer stem cell’ (CSC), referring to a cell that possesses the stem cell abilities of self-renewal and multi-lineage…Read more

Regenerative Medicine Deal Review: January

Author: Mark Curtis, 02/23/15

. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck up a deal to develop a closed, automated cell manufacturing unit for…Read more

Inside a cancer stem cell researcher’s toolbox: CSC markers & flow cytometry

Author: Sara M. Nolte, 12/08/14

> In my previous toolbox articles (sphere formation and xenotransplantation), I’ve talked about assays that are pretty useful in determining the existence of cancer stem cell (CSC) populations based on function. What these assays cannot do is provide us with a way to identify the specific cells. Well, guess what? There’s a tool for that…Read more

Right Turn: New StemCellShorts illuminates cancer stem cells

Author: Ben Paylor, 10/24/14

> Just over one year ago, we launched the pilot phase of an animation project titled StemCellShorts here on Signals blog. Funded by a Stem Cell Network Public Outreach Award, the project was very much an experiment for us to see what would happen when you tasked a team of talented creatives, expert faculty and…Read more

Right Turn: Like a kid’s science show, but for grownups

Author: Stacey Johnson, 09/05/14

. Jordan Green, a biomedical engineer from Johns Hopkins, has a way with words. And toys. He’s like a Mister Rogers (American) or Mr. Dressup (Canadian) for adults. He has a complicated idea to convey, so borrowing from the best children’s entertainers around, he uses colourful props that perfectly suit his friendly demeanor. Dr. Green’s…Read more

Inside a cancer stem cell researcher’s toolbox: Xenotransplantation

Author: Sara M. Nolte, 08/19/14

> In previous posts, I have alluded to the fact that studying cancer in a dish (in vitro) is not optimal (here and here). Today, I give you the next essential tool in a cancer stem cell (CSC) researcher’s toolbox: xenotransplantation. Xenotransplantation is an impressive mouthful that simply means the transplantation of living cells, tissues,…Read more

Update from the Clinic: July

Author: Mark Curtis, 08/18/14

. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational new drug (IND) for SL-401 and initiation of clinical trials in two blood…Read more

Update from the Clinic: June

Author: Mark Curtis, 07/09/14

. Welcome to your Update from the Clinic for the month of June. Neuralstem presented final data on a first-in-class drug for the treatment of major depressive disorder, which is proving to be an effective and non-invasive means to boost brain volume. OncoMed has a shaky start to its Phase I programs targeting the Wnt…Read more

Inside a cancer stem cell researcher’s tool box: Sphere formation

Author: Sara M. Nolte, 06/09/14

> I recently wrote about the dilemma many cancer stem cell (CSC) researchers face when trying to model their disease of interest in the lab. So assuming a researcher has successfully chosen their model – what happens next? Allow me to introduce to you some of the tools-of-the-trade found in any CSC researcher’s tool box….Read more